Atara Biotherapeutics (NASDAQ:ATRA) Releases Quarterly Earnings Results

Atara Biotherapeutics (NASDAQ:ATRA) issued its earnings results on Tuesday. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, FiscalAI reports. Atara Biotherapeutics had a net margin of 27.07% and a negative return on equity of 79.12%. The firm had revenue of $0.52 million during the quarter.

Atara Biotherapeutics Trading Up 11.7%

NASDAQ ATRA opened at $9.81 on Wednesday. Atara Biotherapeutics has a 1-year low of $3.92 and a 1-year high of $19.15. The company has a 50 day moving average of $5.47 and a 200-day moving average of $9.18. The company has a market cap of $83.48 million, a price-to-earnings ratio of 3.14 and a beta of -0.30.

Insider Transactions at Atara Biotherapeutics

In related news, major shareholder Innovation Ltd Panacea sold 313,446 shares of Atara Biotherapeutics stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $10.10, for a total value of $3,165,804.60. Following the transaction, the insider directly owned 1,011,000 shares of the company’s stock, valued at $10,211,100. This trade represents a 23.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 41.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ATRA. Globeflex Capital L P increased its stake in Atara Biotherapeutics by 399.6% in the fourth quarter. Globeflex Capital L P now owns 77,224 shares of the biotechnology company’s stock valued at $1,397,000 after acquiring an additional 61,766 shares during the last quarter. Marshall Wace LLP bought a new position in Atara Biotherapeutics in the second quarter valued at approximately $327,000. Mackenzie Financial Corp increased its stake in Atara Biotherapeutics by 183.5% in the third quarter. Mackenzie Financial Corp now owns 63,816 shares of the biotechnology company’s stock valued at $914,000 after acquiring an additional 41,302 shares during the last quarter. Bridgeway Capital Management LLC increased its stake in Atara Biotherapeutics by 133.5% in the fourth quarter. Bridgeway Capital Management LLC now owns 32,691 shares of the biotechnology company’s stock valued at $591,000 after acquiring an additional 18,691 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Atara Biotherapeutics by 6.6% in the third quarter. Vanguard Group Inc. now owns 203,438 shares of the biotechnology company’s stock valued at $2,915,000 after acquiring an additional 12,677 shares during the last quarter. 70.90% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on ATRA shares. Wall Street Zen downgraded shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Canaccord Genuity Group set a $13.00 target price on Atara Biotherapeutics and gave the company a “buy” rating in a research report on Friday. New Street Research set a $6.00 price target on Atara Biotherapeutics in a report on Tuesday, January 13th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Atara Biotherapeutics in a report on Friday, March 27th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $9.50.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.